For instance, anakinra administered over a 13-week period in T2DM patients increased insulin production, while glycosylated hemoglobin, i.e., HbA1c and the inflammatory marker CRP were significantly reduced (Larsen et al., 2007). The gene discussed is CRP; the disease is type 2 diabetes mellitus.